RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
RIGL$42.05+6.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ (Deficit) Equity
** (In thousands, except number of shares)**
| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · Additional · · Accumulated Other · · · · · Total | ||||||||||||||||||
| · · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’ | ||||||||||||||||||
| · Shares · Amount · Capital · Income (Loss) · Deficit · (Deficit) Equity | ||||||||||||||||||
| Balance as of January 1, 2021 | 169,316,782 | | $169 | | $1,339,833 | | $(4) | | $(1,305,972) | | $34,026 | | ||||||
| Net loss | — | | | — | | | — | | | — | | | (17,914) | | (17,914) | | ||
| Net change in unrealized loss on short-term investments | — | | | — | | | — | | | (98) | | | — | | (98) | | ||
| Issuance of common stock upon exercise of options and participation in Purchase Plan | 2,285,444 | | | 3 | | | 4,772 | | | — | | | — | | 4,775 | | ||
| Stock-based compensation expense | — | | | — | | | 9,585 | | | — | | | — | | 9,585 | | ||
| Balance as of December 31, 2021 | 171,602,226 | | | 172 | | | 1,354,190 | | | (102) | | | (1,323,886) | | | 30,374 | | |
| Net loss | — | | | — | | | — | | | — | | | (58,573) | | (58,573) | | ||
| Net change in unrealized loss on short-term investments | — | | | — | | | — | | | (51) | | | — | | (51) | | ||
| Issuance of common stock upon exercise of options and participation in Purchase Plan | 1,580,169 | | | 2 | | | 2,122 | | | — | | | — | | 2,124 | | ||
| Issuance of common stock upon vesting of restricted stock units (RSUs) | | 216,250 | | | — | | | — | | | — | | | — | | | — | |
| Stock-based compensation expense | — | | | — | | | 12,510 | | | — | | | — | | 12,510 | | ||
| Balance as of December 31, 2022 | | 173,398,645 | | | 174 | | | 1,368,822 | | | (153) | | | (1,382,459) | | | (13,616) | |
| Net loss | — | | | — | | | — | | | — | | | (25,091) | | (25,091) | | ||
| Net change in unrealized gain on short-term investments | — | | | — | | | — | | | 161 | | | — | | 161 | | ||
| Issuance of common stock upon exercise of options and participation in Purchase Plan | 991,959 | | | 1 | | | 1,048 | | | | | | | | 1,049 | | ||
| Issuance of common stock upon vesting of RSUs | | 435,006 | | | — | | | — | | | | | | | | | — | |
| Stock-based compensation expense | — | | | — | | | 8,853 | | | | | | | | 8,853 | | ||
| Balance as of December 31, 2023 | 174,825,610 | | $175 | | $1,378,723 | | $8 | | $(1,407,550) | | $(28,644) | | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.